Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer
18 Years
N/A
Both
Bone Cancer
Trial Information
Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer
The objective of the study is to use 18F sodium fluoride (fluorine F-18 sodium fluoride)
PET/CT scanning to detect and characterize lesions in patients who have suspected skeletal
malignancy. We hypothesize that scanning with 18F-NaF (fluorine F-18 sodium fluoride) is
more sensitive for skeletal abnormalities and may better characterize lesions than
conventional imaging.
Inclusion Criteria:
- Patients referred for evaluation of suspected skeletal cancer
- Patients must understand and voluntarily sign an informed consent form after the
contents have been fully explained to them
Exclusion Criteria:
- Patients who cannot complete a PET/CT scan
- Pregnant women
- Healthy volunteers
Type of Study:
Interventional
Study Design:
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
Number of lesions with fluorine F 18 sodium fluoride PET/CT in patients who have suspected skeletal malignancy
Outcome Description:
Imaging will take approximately two hours in total.
Outcome Time Frame:
2 hours
Safety Issue:
No
Principal Investigator
Andrew Quon
Investigator Role:
Principal Investigator
Investigator Affiliation:
Stanford University
Authority:
United States: Food and Drug Administration
Study ID:
VAR0074
NCT ID:
NCT01541358
Start Date:
May 2012
Completion Date:
Related Keywords:
- Bone Cancer
- Bone Neoplasms
- Osteosarcoma
Name | Location |
|---|---|
| Stanford University | Stanford, California 94305 |
